Core Viewpoint - Bright Minds Biosciences, Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders, and is participating in key upcoming healthcare events [1][2]. Company Overview - Bright Minds Biosciences is a biotechnology company dedicated to creating innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting critical brain receptors [2]. - The company aims to address conditions with high unmet medical needs, including epilepsy and depression, by delivering breakthrough therapies that can significantly improve patients' lives [2]. Product Development - Bright Minds has developed a unique platform of highly selective serotonergic agonists that exhibit selectivity at various serotonergic receptors, resulting in a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [3]. Upcoming Events - The company will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 11:30 am ET [1]. - Additionally, Bright Minds will be present at the 2025 American Epilepsy Society Annual Meeting during the Scientific Exhibit Session on December 7, 2025, from 2 pm to 5 pm ET [1].

Company Overview - Bright Minds Biosciences, Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other central nervous system disorders [1][2] - The company aims to deliver breakthrough therapies that can transform patients' lives, addressing conditions with high unmet medical needs [2] Upcoming Events - Bright Minds will present at the 36th International Epilepsy Congress in Lisbon, Portugal from August 30 to September 3, 2025 [1] - The company will also participate in the Cantor Global Healthcare Conference on September 5, 2025, at 9:45 am ET, with a webcast available [1] - Additional presentations include the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, and the Baird 2025 Global Healthcare Conference on September 10, 2025, both with specific times noted [1] Product Development - The company has developed a unique platform of highly selective serotonergic agonists that exhibit selectivity at different serotonergic receptors, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [3]